This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Adeno-associated virus-like particles
Description: Adeno-associated virus-like particles (AAVLP) are non-infectious and non-replicating protein particles. The virus protein shell, the capsid, is suited for the production of AAVLP, which can be used as a basis for novel vaccines. By inserting short antigenic peptides (B-cell epitopes) into the AAV capsid, a highly specific antibody reaction against selected target molecules can be induced. These antibodies can protect the body or act as a therapy against existing diseases.
Deal Structure: In May 2011, MediGene and The Johns Hopkins University have entered into a development collaboration with the objective of testing vaccine candidates derived from the AAVLP program for the prevention of HPV-associated cancer types, and in so doing to further advance the development of the AAVLP program.
AAVLP Vaccine News
Pink Sheet Wyeth Calls Off Plan To Acquire Crucell
Additional information available to subscribers only: